Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis
- PMID: 8030579
Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis
Abstract
The aim of the present study was to evaluate the efficacy of an oral specific hyposensitization therapy in children with atopic dermatitis and positive prick skin tests and/or RAST to Dermatophagoides pteronyssinus (D.pt.). A total of 60 patients, in three different clinical groups, were selected for a three years clinical trial. Group A: children with atopic dermatitis and allergic asthma and/or rhinitis; groups B and C: children with exclusively atopic dermatitis. Groups A and B received specific hyposensitization therapy. Group C was the control group. The clinical evaluation of the dermatological lesions, at the end of our study, didn't show any significant difference among the three groups. Moreover, the onset of respiratory symptoms between the two groups with exclusively atopic dermatitis was similar and not related to the positivity of prick skin tests and/or RAST to seasonal allergens. Our study suggests that specific hyposensitisation therapy with extracts of D.pt., although with no side effects, does not affect the natural history of atopic dermatitis.
Similar articles
-
[The efficacy of long-term specific immunotherapy for Dermatophagoides pteronyssinus in patients with atopic dermatitis].Recenti Prog Med. 1994 May;85(5):273-7. Recenti Prog Med. 1994. PMID: 8023005 Italian.
-
[Sensitivity to the primary house dust allergen--dermatophagoides pteronyssinus--in patients with atopic dermatitis].Pol Tyg Lek. 1990 Oct 15-29;45(42-44):880-2. Pol Tyg Lek. 1990. PMID: 2098737 Polish.
-
[Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis Part II. Evaluation of skin reactivity and concentration of serum antigen specific immunoglobulin E directed against selected airborne allergens].Wiad Lek. 2005;58(3-4):184-92. Wiad Lek. 2005. PMID: 16119162 Clinical Trial. Polish.
-
[Preventive immunotherapy].Allergol Immunopathol (Madr). 2000 May-Jun;28(3):89-93. Allergol Immunopathol (Madr). 2000. PMID: 10867376 Review. Spanish.
-
Patch test response to house dust mites is positive in children with atopic dermatitis and in their parents.J Investig Allergol Clin Immunol. 1996 May-Jun;6(3):190-5. J Investig Allergol Clin Immunol. 1996. PMID: 8807510 Review.
Cited by
-
Advancements in Allergen Immunotherapy for the Treatment of Atopic Dermatitis.Int J Mol Sci. 2024 Jan 21;25(2):1316. doi: 10.3390/ijms25021316. Int J Mol Sci. 2024. PMID: 38279315 Free PMC article. Review.
-
Is there room for allergen immunotherapy for the treatment of atopic dermatitis in the precision medicine era?Front Pediatr. 2022 Nov 2;10:1050560. doi: 10.3389/fped.2022.1050560. eCollection 2022. Front Pediatr. 2022. PMID: 36405820 Free PMC article. No abstract available.
-
Narrative review on the management of moderate-severe atopic dermatitis in pediatric age of the Italian Society of Pediatric Allergology and Immunology (SIAIP), of the Italian Society of Pediatric Dermatology (SIDerP) and of the Italian Society of Pediatrics (SIP).Ital J Pediatr. 2022 Jun 14;48(1):95. doi: 10.1186/s13052-022-01278-7. Ital J Pediatr. 2022. PMID: 35701810 Free PMC article. Review.
-
Modulating Oxidative Stress in B Cells Promotes Immunotherapy in Food Allergy.Oxid Med Cell Longev. 2022 Jan 21;2022:3605977. doi: 10.1155/2022/3605977. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 35096267 Free PMC article.
-
Consensus Update for Systemic Treatment of Atopic Dermatitis.Ann Dermatol. 2021 Dec;33(6):497-514. doi: 10.5021/ad.2021.33.6.497. Epub 2021 Nov 4. Ann Dermatol. 2021. PMID: 34858001 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical